PDSB (STOCKS)
PDS Biotechnology Corporation Common Stock
$1.009700
-0.040300 (-3.84%)
Prev close: $1.050000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Frank K. Bedu-Addo
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $56.93M
- Employees
- 24
- P/E (TTM)
- -1.52
- P/B (TTM)
- 15.06
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
2
Strong Buy
6
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$-0.13 | $-0.15 | +0.0230 | +15.03% |
|
Dec 2025 (Q4)
|
$-0.15 | $-0.19 | +0.0472 | +24.36% |
|
Sep 2025 (Q3)
|
$-0.19 | $-0.22 | +0.0276 | +12.68% |
|
Jun 2025 (Q2)
|
$-0.21 | $-0.24 | +0.0280 | +11.76% |
Financial Statements
| Revenues | $0.00 |
| Operating Expenses | $28.96M |
| Research and Development | $16.65M |
| Other Operating Expenses | $12.31M |
| Operating Income/Loss | -$28.96M |
| Income/Loss From Continuing Operations After Tax | -$33.36M |
| Income/Loss From Continuing Operations Before Tax | -$33.36M |
| Income Tax Expense/Benefit | $0.00 |
| Income Tax Expense/Benefit, Current | -$1.17M |
| Net Income/Loss | -$33.36M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$33.36M |
| Net Income/Loss Available To Common Stockholders, Basic | -$33.36M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$0.66 |
| Diluted Earnings Per Share | -$0.66 |
| Basic Average Shares | 61,359,558 |
| Diluted Average Shares | 61,359,558 |
| Assets | $24.66M |
| Current Assets | $22.89M |
| Noncurrent Assets | $1.78M |
| Fixed Assets | $114.73K |
| Other Non-current Assets | $1.66M |
| Liabilities | $20.77M |
| Current Liabilities | $10.15M |
| Accounts Payable | $3.65M |
| Other Current Liabilities | $6.50M |
| Noncurrent Liabilities | $10.62M |
| Equity | $3.89M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $3.89M |
| Liabilities And Equity | $24.66M |
| Net Cash Flow From Operating Activities | -$23.09M |
| Net Cash Flow From Operating Activities, Continuing | -$23.09M |
| Net Cash Flow From Investing Activities | $18.32M |
| Net Cash Flow From Investing Activities, Continuing | $18.32M |
| Net Cash Flow From Financing Activities | $4.77M |
| Net Cash Flow From Financing Activities, Continuing | $4.77M |
| Net Cash Flow | $0.00 |
| Net Cash Flow, Continuing | $0.00 |
| Comprehensive Income/Loss | -$33.36M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$33.36M |
| Other Comprehensive Income/Loss | -$7.35M |